EAM Investors’s United Therapeutics UTHR Stock Holding History

EAM Investors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,925	Closed	-$1.4M	–	347
2022 Q2	$1.4M	Buy	+5,925	New	+$1.2M	0.34%	125

Other funds holding UTHR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

EAM Investors's UTHR Position: Q3 2022 in Review

EAM Investors sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 5,925 shares — an estimated $1.4M sold.

EAM Investors first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $1.4M in Q2 2022. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

EAM Investors reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
EAM Investors sold 5,925 United Therapeutics shares in Q3 2022, an estimated $1.4M.
EAM Investors first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
EAM Investors's United Therapeutics position peaked at $1.4M in Q2 2022.
459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on EAM Investors's 13F filing for Q3 2022, filed 14 Nov 2022.